ENXTPA:GDS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Ramsay Générale de Santé

Executive Summary

Ramsay Générale de Santé SA operates hospitals in France.


Snowflake Analysis

Overvalued with weak fundamentals.

Share Price & News

How has Ramsay Générale de Santé's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GDS has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

3.0%

GDS

2.2%

FR Healthcare

8.7%

FR Market


1 Year Return

-0.3%

GDS

0.7%

FR Healthcare

-2.4%

FR Market

Return vs Industry: GDS matched the French Healthcare industry which returned -0.4% over the past year.

Return vs Market: GDS exceeded the French Market which returned -3.8% over the past year.


Shareholder returns

GDSIndustryMarket
7 Day3.0%2.2%8.7%
30 Day-1.4%8.3%15.9%
90 Day-10.6%-8.1%1.3%
1 Year-0.3%-0.3%1.7%0.7%-0.7%-2.4%
3 Year24.5%15.5%9.6%5.2%11.2%2.2%
5 Year36.5%26.6%54.4%43.8%31.1%14.3%

Price Volatility Vs. Market

How volatile is Ramsay Générale de Santé's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Ramsay Générale de Santé undervalued compared to its fair value and its price relative to the market?

215.3x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: GDS (€17.35) is trading above our estimate of fair value (€15.28)

Significantly Below Fair Value: GDS is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: GDS is poor value based on its PE Ratio (215.3x) compared to the Healthcare industry average (29x).

PE vs Market: GDS is poor value based on its PE Ratio (215.3x) compared to the French market (15.1x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GDS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GDS is good value based on its PB Ratio (1.9x) compared to the FR Healthcare industry average (2.2x).


Next Steps

Future Growth

How is Ramsay Générale de Santé forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

17.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ramsay Générale de Santé has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Ramsay Générale de Santé performed over the past 5 years?

-13.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GDS has a large one-off loss of €34.4M impacting its December 31 2019 financial results.

Growing Profit Margin: GDS's current net profit margins (0.2%) are lower than last year (1.2%).


Past Earnings Growth Analysis

Earnings Trend: GDS's earnings have declined by -13.6% per year over the past 5 years.

Accelerating Growth: GDS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: GDS had negative earnings growth (-72.1%) over the past year, making it difficult to compare to the Healthcare industry average (-6.9%).


Return on Equity

High ROE: GDS's Return on Equity (1.5%) is considered low.


Next Steps

Financial Health

How is Ramsay Générale de Santé's financial position?


Financial Position Analysis

Short Term Liabilities: GDS's short term assets (€1.0B) do not cover its short term liabilities (€1.1B).

Long Term Liabilities: GDS's short term assets (€1.0B) do not cover its long term liabilities (€4.1B).


Debt to Equity History and Analysis

Debt Level: GDS's debt to equity ratio (351.6%) is considered high.

Reducing Debt: GDS's debt to equity ratio has increased from 224.5% to 351.6% over the past 5 years.

Debt Coverage: GDS's debt is not well covered by operating cash flow (8.6%).

Interest Coverage: GDS's interest payments on its debt are not well covered by EBIT (1.9x coverage).


Balance Sheet


Next Steps

Dividend

What is Ramsay Générale de Santé's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate GDS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GDS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GDS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GDS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: GDS is not paying a notable dividend for the French market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GDS's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.7yrs

Average board tenure


CEO

Pascal Roché (57yo)

9yrs

Tenure

€1,125,012

Compensation

Mr. Pascal Roché is Chairman of the Board and Chief Executive Officer at Capio AB (publ) since December 4, 2018. Mr. Roché has been the Chief Executive Officer at Ramsay Générale de Santé SA since June 30, ...


CEO Compensation Analysis

Compensation vs Market: Pascal's total compensation ($USD0.00) is below average for companies of similar size in the French market ($USD1.16M).

Compensation vs Earnings: Pascal's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Peter Evans
Director5.67yrs€45.00kno data
Magali Chessé
Director4.42yrs€35.00kno data
Bruce Soden
Director5.67yrs€45.00kno data
Craig McNally
Chairmanno data€45.00kno data
Jean-Jacques Duchamp
Deputy Chairman5.67yrs€55.00kno data
Anne-Marie Couderc
Independent Director6.25yrs€55.00kno data
Carmel Monaghan
Director4.17yrsno datano data
Valérie Hortefeux
Independent Director6.25yrs€45.00kno data
Elvire Kodjo
Director0.75yrno datano data
Olivier Chrétien
Director1.67yrsno datano data

5.7yrs

Average Tenure

55yo

Average Age

Experienced Board: GDS's board of directors are considered experienced (5.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Ramsay Générale de Santé SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Ramsay Générale de Santé SA
  • Ticker: GDS
  • Exchange: ENXTPA
  • Founded: 1987
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Market Cap: €1.915b
  • Shares outstanding: 110.36m
  • Website: https://www.ramsaygds.fr

Number of Employees


Location

  • Ramsay Générale de Santé SA
  • 39 rue Mstislav Rostropovitch
  • Paris
  • Ile-de-France
  • 75017
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GDSENXTPA (Euronext Paris)YesOrdinary SharesFREURJun 2001
GD6DB (Deutsche Boerse AG)YesOrdinary SharesDEEURJun 2001
0OD6LSE (London Stock Exchange)YesOrdinary SharesGBEURJun 2001
GDSPBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURJun 2001

Biography

Ramsay Générale de Santé SA operates hospitals in France. Its hospitals offer a range of services in the areas of anesthesia, oncology, cardiology, dermatology, gastroenterology, gynecology, maternity, nephrology, neurosurgery, obesity, ophthalmology, orthopedics, stomatology, pneumonology, psychiatry, radiology, and urology, as well as heart, hand, digestive, thoracic, vascular, and endovascular surgeries. The company was formerly known as Générale de Santé SA and changed its name to Ramsay Générale de Santé SA in December 2015. Ramsay Générale de Santé SA was founded in 1987 and is based in Paris, France. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/05 21:23
End of Day Share Price2020/06/05 00:00
Earnings2019/12/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.